Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus neoadjuvant chemotherapy for locally advanced cervical cancer
ChiCTR2500113322Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Cervical Cancer (CC), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoint: Pathological complete remission rate. Started Nov 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500113322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113322.